Biolargo, INC. (BLGO) — SEC Filings

Overview

Biolargo, INC. (BLGO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 16, 2026: BioLargo, Inc. filed an EFFECT form on April 16, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-294948. The company's mailing and business address is 14921 Chestnut St., Westminster, CA 92683, with a contact number of 888 400-2863. BioLargo, Inc. is incorporated in De

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 4 bearish, 25 neutral. The dominant filing sentiment for Biolargo, INC. is neutral.

Filing Type Overview

Biolargo, INC. (BLGO) has filed 2 EFFECT, 3 S-1, 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• BioLargo, Inc. Filing Effectiveness Notified — EFFECT · Apr 16, 2026 Risk: low
  BioLargo, Inc. filed an EFFECT form on April 16, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-294948. The company's mailing an
• BioLargo Inc. Registration Statement Declared Effective — EFFECT · Apr 16, 2026 Risk: medium
  BioLargo, Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 16, 2026. The filing, with accession number 9999999995-2
• S-1 Filing — S-1 · Apr 9, 2026
• S-1 Filing — S-1 · Apr 9, 2026
• BioLargo, Inc. Files 8-K Report — 8-K · Nov 18, 2025 Risk: low
  On November 14, 2025, BioLargo, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Nuway Medical Inc., is
• BioLargo's Net Loss Widens to $11M Amidst Revenue Plunge, Credit Loss — 10-Q · Nov 14, 2025 Risk: high
  BIOLARGO, INC. (BLGO) reported a significant net loss of $11.047 million for the nine months ended September 30, 2025, a substantial increase from the $2.615 mi
• BioLargo, Inc. Files 8-K Report — 8-K · Oct 20, 2025 Risk: low
  On October 20, 2025, BioLargo, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure and includes Financial Statements and Exhibits. No spec
• BioLargo, Inc. Terminates Material Agreement, Files 8-K — 8-K · Sep 25, 2025 Risk: medium
  On September 19, 2025, BioLargo, Inc. reported the termination of a material definitive agreement. The company also disclosed material impairments and provided
• BioLargo, Inc. Files 8-K Report — 8-K · Aug 15, 2025 Risk: low
  On August 15, 2025, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the submission of financial statements and e
• BioLargo's Revenue Plummets, Net Loss Widens Amid Going Concern Doubts — 10-Q · Aug 14, 2025 Risk: high
  BIOLARGO, INC. (BLGO) reported a significant decline in revenue and an increased net loss for the six months ended June 30, 2025. Total revenue decreased by 38.
• BioLargo, Inc. Files Current 8-K Report — 8-K · Jul 23, 2025 Risk: low
  On July 23, 2025, BioLargo, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 14921 Chestnut St., Westmins
• BioLargo Files 8-K on Shareholder Vote & Financials — 8-K · Jun 25, 2025 Risk: low
  On June 19, 2025, BioLargo, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The company, form
• BioLargo Reports Q1 2025 Results: Assets Up, Net Loss Continues — 10-Q · May 15, 2025 Risk: medium
  BioLargo, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $301,760,373 as of March 31, 2025, a slight increase fr
• BioLargo Files DEF 14A, Details Executive Pay & Shareholder Votes — DEF 14A · Apr 25, 2025 Risk: medium
  BioLargo, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2024. The
• BioLargo Reports FY2024 Results: Assets $301M, Liabilities $293M — 10-K · Mar 31, 2025 Risk: medium
  BioLargo, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting total assets of $301,274,243 and total liabilities of $292,945,747. The co
• BioLargo, Inc. Files 8-K Report — 8-K · Nov 15, 2024 Risk: low
  On November 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No speci
• BioLargo Reports Q3 2024 Financials — 10-Q · Nov 14, 2024 Risk: high
  BioLargo, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $301,163,538 and total liabilities of $292,945,747
• BioLargo, Inc. Files 8-K Report — 8-K · Aug 15, 2024 Risk: low
  On August 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. N
• BioLargo Reports Q2 2024 Results: Net Loss and Liabilities — 10-Q · Aug 14, 2024 Risk: high
  BioLargo, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $5,562,754 and total liabilities of $10,374,635. For the
• BioLargo Files 8-K on Security Holder Vote & Exhibits — 8-K · Jun 20, 2024 Risk: low
  On June 13, 2024, BioLargo, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The filing also includes financial state
• BioLargo Files 8-K Report — 8-K · Jun 13, 2024 Risk: low
  On June 13, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• BioLargo Files 8-K: Regulation FD & Exhibits — 8-K · May 15, 2024 Risk: low
  On May 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific f
• BioLargo, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
  BIOLARGO, INC. (BLGO) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. BioLargo, Inc. reported a net loss of ($1,057,605) for the three months ende
• BioLargo, Inc. Announces 2024 Annual Meeting of Stockholders on June 13, 2024 — DEF 14A · Apr 26, 2024 Risk: low
  BIOLARGO, INC. (BLGO) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. BioLargo, Inc. will hold its 2024 Annual Meeting of Stockholders on June
• BioLargo, Inc. Files S-1 Registration Statement — S-1 · Apr 12, 2024 Risk: low
  BIOLARGO, INC. (BLGO) filed a IPO Registration (S-1) with the SEC on April 12, 2024. BioLargo, Inc. filed an S-1 registration statement with the SEC on April 12
• Bio-Largo, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  BIOLARGO, INC. (BLGO) filed a Annual Report (10-K) with the SEC on April 1, 2024. Bio-Largo, Inc. reported its 2023 fiscal year-end results on Form 10-K. The co
• BioLargo Files Routine 8-K, Confirms OTCQB Listing — 8-K · Jan 22, 2024
  BioLargo, Inc. filed an 8-K on January 22, 2024, primarily to disclose general information and confirm its status as a public company with Common Stock trading
• BioLargo Files 8-K for Regulation FD Disclosure, Financial Exhibits — 8-K · Jan 10, 2024
  BioLargo, Inc. filed an 8-K on January 10, 2024, to disclose information under Regulation FD and to provide financial statements and exhibits. This filing indic
• BioLargo (BLGO) Changes Certifying Accountant on Jan 2 — 8-K · Jan 5, 2024
  BioLargo, Inc. (BLGO) announced on January 2, 2024, that it has changed its certifying accountant, a significant event for investors. This change, reported in a

Frequently Asked Questions